Approximately 15–20 % of patients in MIRASOL and SORAYA had BRCA1/2 mutations, whereas in our patient population, 32 % of patients had a BRCA mutation and 16 % met criteria for homologous recombination deficiency (HRD). This evidence concerns the gene BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome.